NEW YORK, May 9, 2017 /PRNewswire/ --
A research report by DCAT Connect claims that the total global spend for pharmaceuticals through 2021 will increase by
$367 billion on a constant-dollar basis, according to QuintilesIMS. Spending is measured at the
ex-manufacturer level before adjusting for rebates, discounts, taxes and other calibrations that affect net sales received by
manufacturers. "The outlook for medicine spending growth reflects a more sustainable level for health systems following the
unexpectedly high growth seen in recent years," said Murray Aitken, Senior Vice President and
Executive Director of the QuintilesIMS Institute. "At the same time, the astonishing level of scientific advances for disease
treatments inevitably will place ongoing pressure on funding for medicines - requiring value-based assessments that balance
patient needs and pricing levels with competing healthcare priorities." Quest PharmaTech Inc. (TSX-V: QPT), Theratechnologies
Inc. (OTC: THERF), CRH Medical Corporation (NYSE: CRHM), Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), Concordia International
Corp. (NASDAQ: CXRX).
Another research by Global Market Insights indicates that strong R&D spending trends for synthetic biology to enable drug
and vaccine development, including Europe NEST program will stimulate growth. Organizations including DBT (Department of
Biotechnology) and NTBT (National Biotechnology Board) provides funding for promoting biotechnology market share. The U.S.
biotechnology market size held a dominant position in terms of industry revenue share, with Europe following. This trend is likely to continue throughout the forecast period. The U.S. will further see
increased adoption of products based on these platforms, as growth for personalized medicine becomes a preference.
Quest PharmaTech Inc. (TSX-V: QPT) is a pharmaceutical company developing and commercializing products to improve the
quality of life. Just this morning the company announced that its subsidiary, OncoQuest Inc. ("OncoQuest"), a biopharmaceutical
company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer has completed
the enrollment of the first patient in a Phase 1/2 clinical study to evaluate the use of oregovomab in combination with
Nivolumab, an anti-PD1 human monoclonal antibody which works as a checkpoint inhibitor in ovarian cancer patients in the
recurrent setting. This clinical trial is being conducted at the National Cancer Centre in Singapore ("NCCS"), with Dr. Tira Tan as Principal Investigator, Adjunct
Associate Professor John Chia from Oncocare Cancer Centre as the Study Chair, and Dr. Jack Chan as the co-chair.
"We are extremely excited about launching this study," noted Dr. John Chia. "Ovarian cancer is
a lethal disease, and this trial may offer new hope for our patients. Early clinical data suggests that oregovomab may improve
the immune system's processing of cancer antigens, and enhance the immune ability to recognize these cancer targets. We believe
that the combination of oregovomab and Nivolumab, which amplifies such immune activity, will have a synergistic effect to elicit
a higher quality tumor immune response, and hence improve control of the cancer." This will be the first clinical trial testing
the combination of oregovomab with a checkpoint inhibitor as potential treatment of ovarian cancer in the recurrent setting.
"We continue to explore the potential of oregovomab in various stages of the progression of ovarian cancer," said Dr.
Madiyalakan, CEO of Quest and OncoQuest. In frontline ovarian cancer, OncoQuest has recently announced positive interim results
from its randomized controlled multi-center Phase 2 clinical trial with oregovomab as an indirect immunizer, in scheduled
combination with carboplatin and paclitaxel. "In the recurrent setting, we are exploring the use of oregovomab with immune
adjuvants in two clinical trials. The trial NCCS is conducting is in combination with a checkpoint inhibitor. We are also in the
process of initiating a trial in U.S. in combination with a TLR3 agonist, Hiltonol®," continued Dr. Madiyalakan.
Theratechnologies Inc. (OTC: THERF) is a specialty pharmaceutical company addressing unmet medical needs to promote
healthy living and an improved quality of life among HIV patients. Recently, the company announced that its partner, TaiMed
Biologics, Inc., has completed the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration
(FDA) for ibalizumab for the treatment of multidrug resistant Human Immunodeficiency Virus-1 (MDR HIV-1). If approved, ibalizumab
will be the first antiretroviral treatment (ART) with a new mechanism of action to be introduced in nearly 10 years and the only
treatment that does not require daily dosing.
CRH Medical Corporation (NYSE: CRHM) is a North American company focused on providing gastroenterologists throughout
the United States with innovative services and products for the treatment of gastrointestinal
diseases. On March 15, 2017, the company announced that it has completed an accretive transaction
whereby CRH has acquired a 60% interest in a gastroenterology ("GI") anesthesia practice in Kissimmee
Florida ("Kissimmee"). CRH also announces that it has entered into an exclusive agreement to develop and manage a
monitored anesthesia care ("MAC", or "Deep Sedation") program with Puget Sound Gastroenterology ("PSG"), located in Washington State.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) a clinical stage biopharmaceutical company focused on the global immunology
market, today announced additional 48-week results from its global Phase IIb AURA-LV (AURA) study in lupus nephritis (LN) during
the National Kidney Foundation 2017 Spring Clinical Meetings in Orlando, FL. In addition to the
trial meeting its complete and partial remission ("CR"/"PR") endpoints at 48 weeks, all pre-specified secondary endpoints that
have been analyzed to date were also met at 48 weeks. These pre-specified endpoints include: time to CR and PR (speed of
remission); reduction in Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in urine protein
creatinine ratio (UPCR) over the 48-week treatment period. The data were presented during the late-breaking session by lead
author Dr. Samir Parikh, a clinical investigator for the study and Assistant Professor of Clinical
Nephrology at the Ohio State University.
Concordia International Corp. (NASDAQ: CXRX) together with its subsidiaries is an international specialty
pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs. On January 3rd, the company
announced it has entered into a three-year, co-promotion agreement with RedHill Biopharma Ltd. through which the companies expect
to expand sales of Donnatal®, Concordia's product used in the treatment of irritable bowel syndrome. Concordia's
North America segment seeks to acquire and manage drugs that are in the maturity or legacy stage
of the pharmaceutical product lifecycle and continue on a predictable revenue generation path. These products have a
well-established record of safety and efficacy and a history of stable demand.
Please Sign Up Now at http://www.FinancialBuzz.com to receive alerts
on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in
this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information
posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality
and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not
offer any personal opinions or bias commentary as we purely incorporate public market information along with financial and
corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial
newswire and media platform. For this release, FinancialBuzz.com has been compensated four thousand
dollars for financial news dissemination and PR services by a third party non affiliate for Quest PharmaTech Inc. Our fees
may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a
combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance
is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or
cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the
editorial or Site or continue to post information about any companies the information contained herein is not intended to be used
as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information
contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are
not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles,
quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full
responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own
investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any
pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the
content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular
security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided
by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is
suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult
with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to
the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information
is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer,
disclosure and Terms of Use, please visit: http://www.financialbuzz.com
For further information:
Media Contact:
info@financialbuzz.com
+1-877-601-1879
URL: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com